Post-kala-azar dermal leishmaniasis
Information
- Disease name
- Post-kala-azar dermal leishmaniasis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00486382 | Completed | Phase 1 | Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India | April 2007 | November 2008 |
| NCT01975051 | Completed | Phase 4 | A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) | January 2013 | September 2014 |
| NCT03311607 | Completed | Phase 4 | Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh | April 8, 2014 | October 14, 2015 |
| NCT05449717 | Recruiting | Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan | May 31, 2022 | May 31, 2026 | |
| NCT06251739 | Recruiting | Early Phase 1 | Repurposing Ivermectin for PKDL Treatment | October 30, 2023 | December 2024 |
| NCT04107961 | Withdrawn | Phase 2 | A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL) | October 1, 2023 | July 2025 |